Nervgen Pharma Corp. reports a Return on Equity (ROE) of -843.62%.

What is NGEN's dividend yield?

Nervgen Pharma Corp. offers a dividend yield of 0.00%.

What is NGEN's Quality Score?

Our AI rates NGEN's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NGEN?

Our AI Timing Score for NGEN is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NGEN belong to?

Nervgen Pharma Corp. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Nervgen Pharma Corp. (NGEN) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

NGEN AI Analysis Summary

Our AI summary for NGEN: Nervgen Pharma Corp. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -843.62%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

NGEN

Nervgen Pharma Corp.

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 1.64

0.02 (1.23%) Day Change

Watchlist Portfolio Compare Chart

2.75

D/E

-843.6%

ROE

-225.1%

ROA

0.00%

Div Yield

NERVGEN PHARMA CORP.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.64 Price 0.02 (1.23%) Day Change	NEWS SCORE: N/A

NGEN, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.64
PBV / Sector	31.13 / 44,219.29
Earning Per Share	-0.44

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	1.22 M GREAT
Average 1W Daily Value	0.48 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.22
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-225.13 / 185,260.96
ROA Average (%) / Sector	-158.86 / 36,684.70
ROA Change Average (%) / Sector	35.10 / 422,221.66 GREAT
ROE (%) / Sector	-843.62 / 243,762.23
ROE Average (%) / Sector	-416.82 / 48,758.47
ROE Change Average (%) / Sector	-251.16 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:54
Symbol	NGEN
Name	NERVGEN PHARMA CORP.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	106.41 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	172.39 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 112-970 Burrard Street, Vancouver, BC, Canada, V6Z 2R4

Phone: 778 731 1711

Website: https://nervgen.com

Sector: Healthcare >> Biotechnology

Description: NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.